MedWatch

Lundbeck has initiated phase I trial of acquired candidate

The first patients have been recruited and dosed in a phase I study with a potential new treatment for neurological conditions, Lu AG22515, which Lundbeck acquired last October.

In October, Lundbeck bought a phase I ready candidate from Aprilbio. Now, it's been sent to clinic | Photo: Mik Eskestad/ERH

For the first time, a person has been dosed with Lu AG22515, a candidate that Lundbeck acquired for USD 16m upfront payment from South Korean biotech company Aprilbio in October last year, in a deal which also included potential milestone payments of USD 432m.

Lundbeck revealed this in its first quarterly report for 2021 last week, noting that the study began back in March.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs